Increased tryptophan, but not increased glucose metabolism, predict resistance of pembrolizumab in stage III/IV melanoma

Increased tryptophan, but not increased glucose metabolism, predict resistance of pembrolizumab in stage III/IV melanoma

Clinical trials of combined IDO/PD1 blockade in metastatic melanoma (MM) failed to show additional clinical benefit compared to PD1-alone inhibition. We reasoned that a tryptophan-metabolizing pathway other than the kynurenine one is essential. We immunohistochemically stained tissues along the nevu...

Full description

Bibliographic Details
Main Authors: Jorge D. Oldan, Benjamin C. Giglio, Eric Smith, Weiling Zhao, Deeanna M. Bouchard, Marija Ivanovic, Yueh Z. Lee, Frances A. Collichio, Michael O. Meyers, Diana E. Wallack, Amber Abernethy-Leinwand, Patricia K. Long, Dimitri G. Trembath, Paul B. Googe, Madeline H. Kowalski, Anastasia Ivanova, Jennifer A. Ezzell, Nana Nikolaishvili-Feinberg, Nancy E. Thomas, Terence Z. Wong, David W. Ollila, Zibo Li, Stergios J. Moschos
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:OncoImmunology
Subjects:
IDO1
immunometabolism
metastatic melanoma
TPH1
tryptophan
Online Access:https://www.tandfonline.com/doi/10.1080/2162402X.2023.2204753

Internet

https://www.tandfonline.com/doi/10.1080/2162402X.2023.2204753

Similar Items